Skip to content

COVID-19 Treatment Cascade Optimization Study

COVID-19 Treatment Cascade Optimization Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05305443
Enrollment
554
Registered
2022-03-31
Start date
2022-04-04
Completion date
2023-08-28
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the Comprehensive Behavioral Health Center (CCHC).

Detailed description

This study will use the Multiphase Optimization Strategy (MOST) to optimize an adaptive intervention that successfully navigates COVID-19 medically or socially vulnerable people through a continuum of prevention, care and treatment (CoPCT) modeled on the HIV CoPCT. The COVID-19 CoPCT starts with testing and continues with successful adherence to prevention or treatment guidelines to help prevent and/or treat COVID-19. The study will assess the effectiveness of Navigation Services compared to referrals in increasing COVID-19 testing and Brief Counseling in increasing adherence to the State of IL recommendations for COVID-19 prevention and treatment. The study will also examine the effect of Critical Dialogue on testing behavior among people who decline to be tested for COVID-19. The investigators will develop decision rules about what evidence-based-interventions work best for what types of people (e.g., those who test right away, versus decliners) and in what period of the COVID-19 continuum. Finally, the study will shed light on factors associated with testing and adherence to IL recommendations. Investigators will follow Community Based Participatory Research principles in implementing a sequential, multiple assignment randomized trial (SMART) design. Adjusting for possible 15% loss to follow-up, a total sample of 548 people who are medically and socially vulnerable to infection and poor outcomes with COVID-19 will be enrolled as the intent-to treat-sample. The investigators are confident that they can recruit this sample in St. Clair County, IL based on their previous experience and because the research team has established relationships with other service agencies in the community from which, in addition to CBHC, research participants will be drawn. The primary outcome is completion of the COVID-19 test within one week of the first intervention session. The study will include 3 stages in which participants will be randomized to one of two possible interventions as follows: 1. Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and IL digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session. 2. Those who get tested will be randomized to receive the second-stage intervention: continue with NS or standard treatment or switch to Brief Counseling (BC). The outcome will be adherence to IL recommendations. For those testing positive, adherence means engaging in a 14-day quarantine, receiving medical care as needed and contact tracing. For those testing negative, adherence means social distancing and wearing masks. 3. Those who do not get tested will be randomized into their second-stage intervention to continue with NS or digital brochure or switch to Critical Dialogue (CD). The outcome will be completing COVID-19 testing within 1 week of the second stage intervention session. Those who complete the testing will then be randomized to either continue with NS or digital brochure or switch to BC. Those who do not get tested will be randomized to continued NS or digital brochure or switch to CD. The outcome will be adherence to NJ recommendations, as defined above. All variables will be measured using standardized measures selected from the National Institutes of Health (NIH) PhenX Toolkit. For the primary aim of comparing effects of Navigation Services versus referral on testing behavior and IL recommendations adherence, using standard sample size formula for difference of two proportions, a total sample size of 466 subjects is needed to have 80% power at α=0.05 to detect a 10% difference in proportions, assuming 70% in the referral group will complete testing and adhere to specific IL recommendations. The 466 sample size has 85% to detect a difference of 15% in adherence rates to IL recommendations between two interventions.

Interventions

Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services

Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.

Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.

Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing IL recommendations is e-mailed or texted to participants.

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Comprehensive Behavioral Health Center
CollaboratorUNKNOWN
North Jersey Community Research Initiative
CollaboratorOTHER
University of Michigan
CollaboratorOTHER
University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

SMART Design

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* over 18 years of age * having high risk to contract COVID or develop related complications * able to speak English * able and willing to provide informed consent.

Exclusion criteria

* under 18 years of age * not at high risk to contract COVID or develop related complications * unable to speak English * unable and unwilling to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Completion of COVID-19 TestWithin one week of the intervention sessionEligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and IL digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session.
Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post BaselineStage 2: 6 months post baseline (4th follow up visit)For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.

Countries

United States

Participant flow

Recruitment details

Participants were recruited into the study at the Comprehensive Behavioral Health Center (CBHC), one of southern Illinois' largest and most comprehensive behavioral health providers.

Participants by arm

ArmCount
Navigation (Stage 1) + Navigation (Stage 2)
Participants in this group were randomized in Stage 1 to receive Navigation Services and randomized to receive Navigation Services in Stage 2. Navigation Services: Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
141
Navigation (Stage 1) + Brief Counseling (Stage 2)
Participants in this Group were randomized to receive Navigation services in Stage 1 and randomized to receive Brief Counseling in Stage 2. Brief Counseling: Brief Counseling is a 15-minute post- COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
10
Navigation (Stage 1) + Critical Dialogue (Stage 2)
Participants in this group were randomized to receive Navigation Services in Stage 1 and randomized to receive Critical Dialogue in Stage 2. Critical Dialogue: Critical Dialogue includes three one- hour-long, open- group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities
126
Brochure (Stage 1) + Brochure (Stage 2)
Participants in this group were randomized in stage 1 to receive a digital brochure and randomized to receive a digital brochure in Stage 2. Referral and Digital Brochure: Referral will consist of a five- minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
140
Brochure (Stage 1)+ Brief Counseling (Stage 2)
Participants in this group were randomized in Stage 1 to receive a Brochure and were randomized to receive Brief Counseling in Stage 2. Brief Counseling: Brief Counseling is a 15-minute post- COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
6
Brochure (Stage 1) + Critical Dialogue (Stage 2)
Participants in this group were randomized to receive Navigation Services in Stage 1 and were randomized to receive Critical Dialogue in Stage 2. Critical Dialogue: Critical Dialogue includes three one- hour-long, open- group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
126
Not Randomized After Stage 1
Participants in this group were not randomized following Stage 1
5
Total554

Baseline characteristics

CharacteristicNavigation (Stage 1) + Brief Counseling (Stage 2)Navigation (Stage 1) + Critical Dialogue (Stage 2)Brochure (Stage 1) + Brochure (Stage 2)Brochure (Stage 1)+ Brief Counseling (Stage 2)Navigation (Stage 1) + Navigation (Stage 2)Brochure (Stage 1) + Critical Dialogue (Stage 2)Not Randomized After Stage 1Total
Age, Categorical
<=18 years
0 Participants1 Participants1 Participants0 Participants0 Participants1 Participants0 Participants3 Participants
Age, Categorical
>=65 years
0 Participants6 Participants6 Participants1 Participants7 Participants7 Participants0 Participants27 Participants
Age, Categorical
Between 18 and 65 years
10 Participants119 Participants133 Participants5 Participants134 Participants118 Participants5 Participants524 Participants
COVID tested within previous 30 days4 Participants22 Participants27 Participants3 Participants39 Participants26 Participants1 Participants122 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants6 Participants2 Participants1 Participants7 Participants3 Participants1 Participants20 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
8 Participants106 Participants123 Participants5 Participants121 Participants108 Participants4 Participants475 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants14 Participants15 Participants0 Participants13 Participants15 Participants0 Participants59 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants4 Participants1 Participants0 Participants5 Participants5 Participants0 Participants15 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
9 Participants93 Participants106 Participants3 Participants112 Participants92 Participants4 Participants419 Participants
Race (NIH/OMB)
More than one race
0 Participants6 Participants6 Participants0 Participants1 Participants3 Participants0 Participants16 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants1 Participants0 Participants0 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants5 Participants6 Participants1 Participants9 Participants4 Participants1 Participants26 Participants
Race (NIH/OMB)
White
1 Participants18 Participants20 Participants2 Participants14 Participants21 Participants0 Participants76 Participants
Region of Enrollment
United States
10 Participants126 Participants140 Participants6 Participants141 Participants126 Participants5 Participants554 Participants
Sex/Gender, Customized
Female
6 participants66 participants63 participants4 participants74 participants73 participants2 participants288 participants
Sex/Gender, Customized
Male
4 participants54 participants73 participants1 participants60 participants48 participants3 participants243 participants
Sex/Gender, Customized
Unknown/Unreported
0 participants6 participants4 participants1 participants7 participants5 participants0 participants23 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
deaths
Total, all-cause mortality
0 / 2780 / 1380 / 100 / 1260 / 2730 / 1280 / 60 / 1220 / 5
other
Total, other adverse events
0 / 2780 / 1380 / 100 / 1260 / 2730 / 1280 / 60 / 1220 / 5
serious
Total, serious adverse events
0 / 2780 / 1380 / 100 / 1260 / 2730 / 1280 / 60 / 1220 / 5

Outcome results

Primary

Completion of COVID-19 Test

Eligible and consenting participants will be randomized to receive the first-stage intervention: Navigation Services (NS) or standard services (referral to testing and IL digital information brochure after testing). The primary outcome is completion of the COVID-19 test within one week of the intervention session.

Time frame: Within one week of the intervention session

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Navigation (Stage 1)Completion of COVID-19 Test72 Participants
Brochure OnlyCompletion of COVID-19 Test60 Participants
Primary

Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline

For the second stage intervention, the primary outcome is self-reported completion of COVID-19 test in the past 30 days at the follow up completed 6 months after baseline. Study participants were asked whether they had completed a COVID-19 test in the past 30 days.

Time frame: Stage 2: 6 months post baseline (4th follow up visit)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Navigation (Stage 1)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline39 Participants
Brochure OnlyStage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline4 Participants
Navigation (Stage 1) + Critical Dialogue (Stage 2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline23 Participants
Brochure (Stage 1) + Brochure (Stage 2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline27 Participants
Brochure (Stage 1)+ Brief Counseling (Stage 2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline3 Participants
Brochure (Stage 1) + Critical Dialogue (Stage 2)Stage 2: Reported COVID Test in Last 30 Days at 6 Months Post Baseline26 Participants

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026